News / Events

Featured News Stories

  • November 18, 2008

    CLINPAGE DISCUSSES STRATEGY BEHIND CLINSYS' ACQUISITION OF TRIALSTAT CLINICALANALYTICS
    View Article

  • November 17, 2008

    JUBILANT AUGMENTS CLINSYS CLINICAL RESEARCH® THROUGH ACQUISITION OF TRIALSTAT CLINICALANALYTICS®, AN EDC PLATFORM
    Download PDF | View Short Summary

    NOIDA, INDIA (November 17, 2008) - Jubilant Organosys Ltd. announced today that its subsidiary Clinsys Clinical Research, Inc.®, New Jersey, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics® from TrialStat® for a purchase consideration of CAD 750,000.

    TrialStat ClinicalAnalytics (TrialStat CA) is a Web-based electronic data capture (EDC) solution currently used by a wide range of pharmaceutical and CRO customers worldwide. TrialStat CA is the industry's first EDC platform to allow all aspects of a study to be configured, deployed and managed through a browser interface, enabling customers to start their studies quickly and cost-effectively.

    Clinsys extensive global resources will enable TrialStat to continue its proven record of growth, customer service and product innovation. This agreement will give TrialStat's existing CRO and biopharmaceutical customer base a broader scope of services.

    "The Company had identified TrialStat ClinicalAnalytics as one of the most innovative EDC solutions on the market and was determined to include it in its offerings to its customers globally" said David E. Williams, Chief Executive Officer of Clinsys.

  • October 1, 2008

    CLINSYS® SUPPORTS BREAST CANCER RESEARCH THROUGH PASSIONATELY PINK FOR THE CURE® INITIATIVE
    Download PDF | View Short Summary

    BEDMINSTER, NEW JERSEY (October 1, 2008) - Clinsys Clinical Research, a therapeutically focused global contract research organization, today announced the launch of its Passionately Pink for the Cure ® campaign, a company-wide breast cancer awareness and fundraising program supporting Susan G. Komen for the Cure® . All donations received through the year-long Clinsys Passionately Pink campaign will be matched by the company.

    Passionately Pink for the Cure is a national grassroots program in which companies, organizations, social groups and individuals select a day to wear pink, and each group member donates $5 or more to Komen for the Cure. Of the donations received through Passionately Pink for the Cure, 75 percent will go toward breast cancer research, and the remaining 25 percent will be shared with Komen affiliates to support local education, screening and treatment efforts.

  • July 31, 2008

    CLINSYS® DIRECTOR RECOGNIZED AS INDUSTRY INSPIRATION
    Download PDF | View Short Summary

    BEDMINSTER, NEW JERSEY (July 31, 2008) - Clinsys Clinical Research, a therapeutically focused global contract research organization, today announced that Nila Williams, Director, Customer Relations and Global Training, has been selected as one of the "100 Most Inspiring People in the Life-Sciences Industry in 2008" by the readers of PharmaVOICE magazine. Recognition is based on how individuals have inspired and motivated those around them, their influence as a corporate leader, and how their actions have positively impacted the industry.

  • July 7, 2008

    CLINSYS® CEO FEATURED IN KORN/FERRY EMERGING CROs WHITE PAPER
    Download PDF | View Short Summary

    The thought leadership of David E. Williams, Chief Executive Officer of Clinsys Clinical Research, Inc.®, is featured in Emerging Contract Research Organizations: Driving Success, a white paper by Bob Ferguson and Ruchira Pathania recently published by Korn/Ferry International. The paper explores how CROs are transforming the global pharmaceutical and biotechnology landscape and examines the strategies and leadership skills that are proving successful for these organizations.

    For additional information about Korn/Ferry International's thought leadership publications, please visit www.kornferry.com/ThoughtLeadership.

  • May 30, 2008

    CLINSYS® PARTNERS WITH MEDIDATA SOLUTIONS THROUGH ASPIRE TO WIN PARTNER PROGRAM
    Download PDF | View Short Summary

    NEW YORK, N.Y. and BEDMINSTER, N.J.- May 30, 2008 - Medidata Solutions, a leading provider of clinical trial solutions, and Clinsys Clinical Research, Inc.® , a therapeutically focused global contract research organization (CRO), today announced that the two companies have partnered through Medidata's ASPire to Win® program. The partnership will enable Clinsys to implement the Medidata Rave® technology for capturing, managing and reporting clinical data as a complement to its focus on superior service delivery for sponsors in the U.S., Europe and India.

    Clinsys provides pharmaceutical, biotechnology and medical device companies with a full range of clinical research services in support of Phase I-IV drug and device development. With extensive experience and expertise in specialized therapeutic areas including oncology, central nervous system, dermatology, respiratory and cardiovascular, Clinsys looked for an electronic data capture (EDC) partner that offered innovative Web-based technology with secure, reliable and scalable hosting, in order to reduce both implementation time and total cost of ownership. Clinsys selected Medidata as its EDC provider due to sponsor demand for Rave's Web-based, site-friendly features that help to increase EDC usage.

  • May 28, 2008

    JUBILANT SUCCESSFULLY COMPLETES ACQUISITION OF DRAXIS
    Download PDF | View Short Summary

    INDIA (May 28, 2008) - Jubilant Organosys Ltd., an integrated pharmaceutical industry player and India's largest Custom Research and Manufacturing Services (CRAMS) company, today announced the completion of the transaction to acquire Canada-based DRAXIS Health Inc. (DRAXIS) for US $253 million. DRAXIS operates an FDA-approved manufacturing facility in Montreal, Canada, and employs approximately 500.

    DRAXIS offers products in three categories: sterile products, non-sterile products and radiopharmaceuticals. Sterile products include liquid and freeze-dried (lyophilized) injectables plus sterile ointments and creams. Non-sterile products are produced as solid oral and semi-solid dosage forms. Radiopharmaceuticals are used for both therapeutic and diagnostic molecular imaging applications.

  • April 10, 2008

    CLINSYS® REDEFINES RESOURCE SERVICES WITH THE LAUNCH OF CLINSYS ALTERNA™
    Download PDF | View Short Summary

    CLINSYS® REDEFINES RESOURCE SERVICES WITH THE LAUNCH OF CLINSYS ALTERNA™

    BEDMINSTER, NEW JERSEY (April 10, 2008) - Clinsys Clinical Research, a therapeutically focused global contract research organization, today announced the launch of Clinsys ALTERNA, which utilizes its Global Project Solution® (Clinsys GPS®) to augment clinical resource services. The new division demonstrates Clinsys' commitment to aligning its service offerings with its sponsors' and the life sciences industry's continuously evolving staffing needs.

    Clinsys ALTERNA provides customized Phase I-IV clinical trial alternative solutions to the conventional outsourcing model. The division is a core element of Clinsys GPS, a unique, highly effective and proven integrated project management solution that brings the sponsor and the Clinsys project teams together to collaborate and agree on all aspects of the clinical study—before, during and after—to ensure the project's success.

  • April 9, 2008

    CLINSYS® TPS TEAMS PROVIDE COMPREHENSIVE CLINICAL DEVELOPMENT PLANS

    Clinsys continues expansion of team and drug development and clinical trial design capabilities through Therapeutically-aligned Program Strategists.

    Download PDF | View Short Summary

    CLINSYS® TPS TEAMS PROVIDE COMPREHENSIVE CLINICAL DEVELOPMENT PLANS

    BEDMINSTER, NEW JERSEY - April 9, 2008 - Clinsys Clinical Research, Inc.®, a therapeutically focused global contract research organization (CRO), today introduced its Therapeutically-aligned Program Strategists (TPS), an innovative concept for the evaluation and execution of clinical trials. The TPS teams are comprised of highly skilled and experienced professionals with defined therapeutic expertise who evaluate, create and execute all sponsor projects, from clinical development plans and clinical trial design through protocol finalization, leading to successful trial conduct.

    Each TPS team consists of MDs, PhDs and a clinical operations program director with expertise in a specific therapeutic area. These strategists apply a research-oriented approach to clinical trial strategy, design and execution to either deliver a comprehensive clinical development plan or protocol, or review and critique client synopses and protocols. The TPS team also provides analysis of the competitive environment, the current standards of care and market potential. TPS services extend to design and implementation of generic and bioavailability/bioequivalence (BA/BE) trials.

Upcoming Conferences